Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study

Background Follicular lymphoma (FL) is an indolent, yet incurable B cell malignancy. A subset of patients experience an increased mortality rate driven by two distinct clinical end points: histological transformation and early progression after immunochemotherapy. The nature of tumor clonal dynamics leading to these clinical end points is poorly understood, and previously determined genetic alterations do not explain the majority of transformed cases or accurately predict early progressive disease. We contend that detailed knowledge of the expansion patterns of specific cell populations plus their associated mutations would provide insight into therapeutic strategies and disease biology over the time course of FL clinical histories. Methods and Findings Using a combination of whole genome sequencing, targeted deep sequencing, and digital droplet PCR on matched diagnostic and relapse specimens, we deciphered the constituent clonal populations in 15 transformation cases and 6 progression cases, and measured the change in clonal population abundance over time. We observed widely divergent patterns of clonal dynamics in transformed cases relative to progressed cases. Transformation specimens were generally composed of clones that were rare or absent in diagnostic specimens, consistent with dramatic clonal expansions that came to dominate the transformation specimens. This pattern was independent of time to transformation and treatment modality. By contrast, early progression specimens were composed of clones that were already present in the diagnostic specimens and exhibited only moderate clonal dynamics, even in the presence of immunochemotherapy. Analysis of somatic mutations impacting 94 genes was undertaken in an extension cohort consisting of 395 samples from 277 patients in order to decipher disrupted biology in the two clinical end points. We found 12 genes that were more commonly mutated in transformed samples than in the preceding FL tumors, including TP53, B2M, CCND3, GNA13, S1PR2, and P2RY8. Moreover, ten genes were more commonly mutated in diagnostic specimens of patients with early progression, including TP53, BTG1, MKI67, and XBP1. Conclusions Our results illuminate contrasting modes of evolution shaping the clinical histories of transformation and progression. They have implications for interpretation of evolutionary dynamics in the context of treatment-induced selective pressures, and indicate that transformation and progression will require different clinical management strategies.

[1]  M. Oken,et al.  Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer. , 1987, The New England journal of medicine.

[2]  D. Longo,et al.  MYC rearrangements in histologically progressed follicular lymphomas. , 1992, Blood.

[3]  K. Offit,et al.  p53 mutations are associated with histologic transformation of follicular lymphoma. , 1993, Blood.

[4]  D. Longo,et al.  p53 mutation is associated with progression in follicular lymphomas. , 1993, Blood.

[5]  p53 mutations are associated with histologic transformation of follicular lymphoma , 1993 .

[6]  Annick,et al.  Prognostic value of chromosomal abnormalities in follicular lymphoma. , 1994, Blood.

[7]  B. Nathwani,et al.  A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .

[8]  James Olen Armitage,et al.  A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. , 1997, Blood.

[9]  D. Weisenburger,et al.  Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  David Botstein,et al.  Transformation of follicular lymphoma to diffuse large-cell lymphoma: Alternative patterns with increased or decreased expression of c-myc and its regulated genes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Tom H. Pringle,et al.  The human genome browser at UCSC. , 2002, Genome research.

[12]  Mattias Höglund,et al.  Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas , 2004, Genes, chromosomes & cancer.

[13]  Maido Remm,et al.  Enhancements and modifications of primer design program Primer3 , 2007, Bioinform..

[14]  M. Calaminici,et al.  Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Jan Delabie,et al.  Transformation of follicular lymphoma to diffuse large B‐cell lymphoma proceeds by distinct oncogenic mechanisms , 2007, British journal of haematology.

[16]  T. Lister,et al.  Genome-wide detection of recurring sites of uniparental disomy in follicular and transformed follicular lymphoma , 2007, Leukemia.

[17]  W. Chan,et al.  Clonal Evolution in t(14;18)-Positive Follicular Lymphoma, Evidence for Multiple Common Pathways, and Frequent Parallel Clonal Evolution , 2008, Clinical Cancer Research.

[18]  L. Staudt,et al.  The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. , 2008, Blood.

[19]  Randy D Gascoyne,et al.  Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Gribben,et al.  Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone. , 2009, Blood.

[21]  L. Staudt,et al.  Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. , 2009, Blood.

[22]  Christian Steidl,et al.  Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances. , 2009, Blood.

[23]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[24]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[25]  Michael R. Green,et al.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. , 2010, Blood.

[26]  Gergely J. Szöllősi,et al.  Emergent Neutrality in Adaptive Asexual Evolution , 2011, Genetics.

[27]  Dereje D. Jima,et al.  The genetic landscape of mutations in Burkitt lymphoma , 2012, Nature Genetics.

[28]  L. Staudt,et al.  Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics , 2012, Nature.

[29]  S. C. Sahinalp,et al.  nFuse: Discovery of complex genomic rearrangements in cancer using high-throughput sequencing , 2012, Genome research.

[30]  Wendy S. W. Wong,et al.  Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs , 2012, Bioinform..

[31]  Ken Chen,et al.  Clonal architecture of secondary acute myeloid leukemia. , 2012, The New England journal of medicine.

[32]  R. Spang,et al.  Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing , 2012, Nature Genetics.

[33]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[34]  Joshua F. McMichael,et al.  Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.

[35]  Gholamreza Haffari,et al.  Feature-based classifiers for somatic mutation detection in tumour–normal paired sequencing data , 2011, Bioinform..

[36]  B. Faircloth,et al.  Primer3—new capabilities and interfaces , 2012, Nucleic acids research.

[37]  R. Houot,et al.  Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma , 2013, Haematologica.

[38]  Trevor J Pugh,et al.  Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation , 2013, Nucleic acids research.

[39]  Raul Rabadan,et al.  Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome , 2013, The Journal of experimental medicine.

[40]  J. Cerhan,et al.  Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .

[42]  A. McKenna,et al.  Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia , 2012, Cell.

[43]  Summer S. Han,et al.  Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. , 2013, Blood.

[44]  A. Bouchard-Côté,et al.  PyClone: statistical inference of clonal population structure in cancer , 2014, Nature Methods.

[45]  Adrien B. Larsen,et al.  Loss of signaling via Gα13 in germinal center B cell-derived lymphoma , 2014, Nature.

[46]  Sohrab P. Shah,et al.  TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data , 2014, Genome research.

[47]  V. Kukreti,et al.  Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis , 2014, Leukemia & lymphoma.

[48]  E. Kimby,et al.  Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry Study , 2014, Leukemia.

[49]  Raul Rabadan,et al.  Genetics of follicular lymphoma transformation. , 2014, Cell reports.

[50]  H. Feilotter,et al.  Inactivation of the CDKN2A Tumor-Suppressor Gene by Deletion or Methylation Is Common at Diagnosis in Follicular Lymphoma and Associated with Poor Clinical Outcome , 2014, Clinical Cancer Research.

[51]  Kai Fu,et al.  Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. , 2014, Blood.

[52]  M. Calaminici,et al.  Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma , 2013, Nature Genetics.

[53]  R. Gascoyne,et al.  Cell of origin of transformed follicular lymphoma. , 2015, Blood.

[54]  Martin A. Nowak,et al.  Mutations driving CLL and their evolution in progression and relapse , 2015, Nature.

[55]  Ash A. Alizadeh,et al.  Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation , 2015, Proceedings of the National Academy of Sciences.

[56]  Nilgun Donmez,et al.  Clonality inference in multiple tumor samples using phylogeny , 2015, Bioinform..

[57]  A. Stroux,et al.  Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis , 2015, Annals of Hematology.

[58]  Robert Kridel,et al.  Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. , 2015, The Lancet. Oncology.

[59]  J. Friedberg,et al.  Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). , 2015, Blood.

[60]  J. Cerhan,et al.  Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  Gary D. Bader,et al.  Divergent clonal selection dominates medulloblastoma at recurrence , 2016, Nature.

[62]  Eric Talevich,et al.  CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing , 2016, PLoS Comput. Biol..

[63]  Franziska Wulf,et al.  Mathematical Population Genetics , 2016 .

[64]  A. Rosenwald,et al.  Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. , 2016, Blood.